Tuesday, November 17, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home IPOs

AIM ImmunoTech Launches Equity Offering to Fund Clinical Pipeline

SiterGedge by SiterGedge
February 11, 2026
in IPOs, Penny Stocks, Pharma & Biotech
0
AIM ImmunoTech Stock
0
SHARES
63
VIEWS
Share on FacebookShare on Twitter

AIM ImmunoTech has initiated a critical financing effort to support its ongoing clinical programs. The biotechnology firm announced the commencement of a rights offering today, coinciding with an investor webinar. The central question for stakeholders is whether the targeted capital will be sufficient to advance the company’s lead drug candidate, Ampligen, through its ambitious trial objectives.

Concurrently with the offering, company management is hosting a conference to update investors on clinical progress, particularly for the DURIPANC Phase 2 study. This trial is evaluating Ampligen in combination with AstraZeneca’s immunotherapy drug, Imfinzi, as a treatment for metastatic pancreatic cancer.

Key Clinical Trial Status:
* Patient Recruitment: 18 out of a planned 25 patients have already been enrolled at the Erasmus University Medical Center.
* Study Design: The trial focuses on patients with stable disease following prior FOLFIRINOX treatment.
* Supporting Data: Preliminary observations from earlier programs indicated a median overall survival of 19.7 months for the combination therapy, compared to 8.6 months for the previous standard of care.

Financing Details and Strategic Use of Funds

The rights offering follows a record date set for February 10. Eligible shareholders will receive non-transferable rights to purchase new equity units. Each unit consists of newly designated Series G convertible preferred stock and accompanying warrants.

Should investors sell immediately? Or is it worth buying AIM ImmunoTech?

Primary Terms of the Offering:
* Gross Proceeds Target: Approximately $12 million.
* Subscription Period: Began today and is scheduled to conclude on February 27, 2026, unless extended.
* Allocation of Capital: Funds are designated for covering operational costs, manufacturing Ampligen to supply clinical programs, and reducing existing corporate debt.

The successful completion of this capital raise is viewed as essential for maintaining operational stability over the coming months. Management aims to secure the necessary resources to proceed with the next phase of the DURIPANC study and ensure uninterrupted drug production.

Investor attention is now fixed on whether the company can achieve its full $12 million funding goal. The outcome will directly impact AIM ImmunoTech’s ability to execute its clinical strategy for Ampligen without encountering financial constraints.

Ad

AIM ImmunoTech Stock: Buy or Sell?! New AIM ImmunoTech Analysis from November 17 delivers the answer:

The latest AIM ImmunoTech figures speak for themselves: Urgent action needed for AIM ImmunoTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 17.

AIM ImmunoTech: Buy or sell? Read more here...

Tags: AIM ImmunoTech
SiterGedge

SiterGedge

Related Posts

Novo Nordisk Stock
Analysis

Novo Nordisk Faces a New Front: 300-Fold Rise in GLP-1 Scripts for Children Under 12

September 7, 2026
Novo Nordisk Stock
European Markets

Novo Nordisk’s Two-Front Battle: US Price Concessions Meet a Pipeline Fighting for Credibility

September 6, 2026
Valneva Stock
European Markets

Valneva’s Cash Cushion Grows Even as First-Half Losses Deepen

September 6, 2026
Next Post
Cardano Stock

Cardano's Institutional Debut Fails to Ignite Market Rally

Meta Materials Stock

The Final Chapter: Meta Materials Enters Liquidation Phase

Singularity Future Technology Stock

Singularity Future Technology: Upcoming Financial Report to Gauge Strategic Shift

Recommended

Mirum Pharmaceuticals Stock

Mirum Pharmaceuticals: A Pivotal Year of Clinical Catalysts and Financial Milestones

8 months ago
Marvell Technology Stock

Marvell Technology’s AI Business Fuels Record Quarter Amid Mixed Segment Performance

1 year ago
Ondas Holdings Stock

Ondas Holdings: Can New Contracts Reignite Its Stalled Momentum?

12 months ago
Block Stock

A Tale of Two Titans: Block and PayPal’s Divergent Fintech Paths

1 year ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum DroneShield Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

The AI Rebound Gets an Audit: Who Earns, Who Borrows

A Hot CPI Reading Stalls the Rebound and Puts a December Hike in Play

Cash Over Stories: Take-Two, Cisco and Nvidia Face Their Tests

Four Down Weeks for the Nasdaq, and Consumer Stocks Quietly Cash In

Trending

Home Depot Stock
Newsletter

Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers

by Stephanie Dugan
November 17, 2026
0

Dear readers, Home Depot did what it was supposed to do on Tuesday morning and got little...

Bitcoin Stock

Rotation, Not Panic: Retailers Test Where Tech’s Money Went

November 16, 2026
Cisco Stock

At 5.15%, the 10-Year Treasury Picks the Winners

November 14, 2026
Bitcoin Stock

Bitcoin Slips Below $70,000, and a Samsung Rumor Lifts Modine

November 13, 2026
Cisco Stock

Huang Exits, Cisco Reports: Who Actually Gets Paid for AI

November 12, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Home Depot Beats, Shares Slip: Bigger Tickets, Fewer Customers
  • Rotation, Not Panic: Retailers Test Where Tech’s Money Went
  • At 5.15%, the 10-Year Treasury Picks the Winners

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com